137 related articles for article (PubMed ID: 10667430)
1. Persistence of high-grade prostatic intra-epithelial neoplasia under combined androgen blockade therapy.
van der Kwast TH; Labrie F; Tetu B
Hum Pathol; 1999 Dec; 30(12):1503-7. PubMed ID: 10667430
[TBL] [Abstract][Full Text] [Related]
2. Influence of irradiation and androgen ablation on prostatic intraepithelial neoplasia.
Wheeler TM
Eur Urol; 1996; 30(2):261-4. PubMed ID: 8875209
[TBL] [Abstract][Full Text] [Related]
3. Androgen receptors in untreated and treated prostatic intraepithelial neoplasia.
van der Kwast TH; Têtu B
Eur Urol; 1996; 30(2):265-8. PubMed ID: 8875210
[TBL] [Abstract][Full Text] [Related]
4. Pathology of androgen deprivation therapy in prostate carcinoma. A comparative study of 173 patients.
Civantos F; Marcial MA; Banks ER; Ho CK; Speights VO; Drew PA; Murphy WM; Soloway MS
Cancer; 1995 Apr; 75(7):1634-41. PubMed ID: 8826921
[TBL] [Abstract][Full Text] [Related]
5. Decrease of prostatic intraepithelial neoplasia following androgen deprivation therapy in patients with stage T3 carcinoma treated by radical prostatectomy.
Ferguson J; Zincke H; Ellison E; Bergstrahl E; Bostwick DG
Urology; 1994 Jul; 44(1):91-5. PubMed ID: 8042266
[TBL] [Abstract][Full Text] [Related]
6. Functional heterogeneity of prostatic intraepithelial neoplasia: the duration of hormonal therapy influences the response.
Kang TY; Nichols P; Skinner E; Groshen S; Valin G; Ye W; Raghavan D
BJU Int; 2007 May; 99(5):1024-7. PubMed ID: 17244277
[TBL] [Abstract][Full Text] [Related]
7. Vascular endothelial growth factor expression and capillary architecture in high-grade PIN and prostate cancer in untreated and androgen-ablated patients.
Mazzucchelli R; Montironi R; Santinelli A; Lucarini G; Pugnaloni A; Biagini G
Prostate; 2000 Sep; 45(1):72-9. PubMed ID: 10960845
[TBL] [Abstract][Full Text] [Related]
8. Pathologic effects of neoadjuvant cyproterone acetate on nonneoplastic prostate, prostatic intraepithelial neoplasia, and adenocarcinoma: a detailed analysis of radical prostatectomy specimens from a randomized trial.
Bullock MJ; Srigley JR; Klotz LH; Goldenberg SL
Am J Surg Pathol; 2002 Nov; 26(11):1400-13. PubMed ID: 12409716
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant hormonotherapy in patients with clinically-localized prostate cancer treated by radical prostatectomy: pathological results.
Têtu B
Can J Oncol; 1994 Nov; 4 Suppl 1():33-4; discussion 35-6. PubMed ID: 8853487
[No Abstract] [Full Text] [Related]
10. Effect of neoadjuvant hormonal therapy on prostatic intraepithelial neoplasia and its prognostic significance.
Balaji KC; Rabbani F; Tsai H; Bastar A; Fair WR
J Urol; 1999 Sep; 162(3 Pt 1):753-7. PubMed ID: 10458359
[TBL] [Abstract][Full Text] [Related]
11. Histopathological effects of androgen deprivation in prostatic cancer.
Civantos F; Soloway MS; Pinto JE
Semin Urol Oncol; 1996 May; 14(2 Suppl 2):22-31. PubMed ID: 8725888
[TBL] [Abstract][Full Text] [Related]
12. Prostatic intraepithelial neoplasia and endocrine manipulation.
van der Kwast TH; Labrie F; Têtu B
Eur Urol; 1999; 35(5-6):508-10. PubMed ID: 10325515
[TBL] [Abstract][Full Text] [Related]
13. Intermediate biomarkers for chemoprevention of prostate cancer.
van der Kwast TH
IARC Sci Publ; 2001; 154():199-205. PubMed ID: 11220659
[TBL] [Abstract][Full Text] [Related]
14. Chemoprevention for prostatic carcinoma: The role of flutamide in patients with prostatic intraepithelial neoplasia.
Alberts SR; Blute ML
Urology; 2001 Apr; 57(4 Suppl 1):188-90. PubMed ID: 11295624
[TBL] [Abstract][Full Text] [Related]
15. Short term neoadjuvant androgen deprivation therapy does not affect prostate specific membrane antigen expression in prostate tissues.
Chang SS; Reuter VE; Heston WD; Hutchinson B; Grauer LS; Gaudin PB
Cancer; 2000 Jan; 88(2):407-15. PubMed ID: 10640975
[TBL] [Abstract][Full Text] [Related]
16. Extent and zonal distribution of prostatic intraepithelial neoplasia in patients with prostatic carcinoma in Japan: analysis of whole-mounted prostatectomy specimens.
Shin M; Takayama H; Nonomura N; Wakatsuki A; Okuyama A; Aozasa K
Prostate; 2000 Feb; 42(2):81-7. PubMed ID: 10617864
[TBL] [Abstract][Full Text] [Related]
17. Pseudomyxoma ovariilike posttherapeutic alteration in prostatic adenocarcinoma: a distinctive pattern in patients receiving neoadjuvant androgen ablation therapy.
Tran TA; Jennings TA; Ross JS; Nazeer T
Am J Surg Pathol; 1998 Mar; 22(3):347-54. PubMed ID: 9500777
[TBL] [Abstract][Full Text] [Related]
18. PSA levels and the rate of positive surgical margins in radical prostatectomy specimens preceded by androgen blockade in clinical B2 (T2bNxMo) prostate cancer. The Lupron Depot Neoadjuvant Study Group.
McLeod DG; Johnson CF; Klein E; Peabody JO; Coffield S; Soloway M
Urology; 1997 Mar; 49(3A Suppl):70-3. PubMed ID: 9123740
[TBL] [Abstract][Full Text] [Related]
19. High-grade prostatic intraepithelial neoplasialike ductal adenocarcinoma of the prostate: a clinicopathologic study of 28 cases.
Tavora F; Epstein JI
Am J Surg Pathol; 2008 Jul; 32(7):1060-7. PubMed ID: 18496142
[TBL] [Abstract][Full Text] [Related]
20. Cytological features of prostatic intraepithelial neoplasia.
Valdman A; Jonmarker S; Ekman P; Egevad L
Diagn Cytopathol; 2006 May; 34(5):317-22. PubMed ID: 16604550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
